Lisätietoja julkaisusta saa klikkaamalla sen numeroa.
For full details, please click the number in front of the publication.
1 |
Halonen T et al. |
Changes in amino acid levels in rat brain during chronic vigabatrin treatment.
|
2 |
Halonen T et al. |
GABA levels in human and rat CSF during vigabatrin treatment.
|
3 |
Halonen T et al. |
Effect of administration of vigabatrin on GABA levels and on GABA/benzodiazepine receptor binding in rat brain.
|
4 |
Helkala EL et al. |
Association of quantitative spectral analysis of EEG with neurophysiological functions in patients with dementia.
|
5 |
Helkala EL et al. |
Different error pattern of episodic and semantic memory in Alzheimer's disease and Parkinson's disease with dementia.
|
6 |
Helkala EL et al. |
Recall and recognition memory in patients with Alzheimer's and Parkinson's disease.
|
7 |
Jolkkonen J et al. |
Vasopressin levels in CSF of Alzheimer patients: Correlations with monoamine metabolites and neuropsychological test performance.
|
8 |
Keränen T et al. |
Incidence and prevalence of epilepsy in adults in Eastern Finland.
|
9 |
Koponen H. |
Delirium in the elderly: A clinical, neurochemical, neuropsychological and neuroradiological study.
|
10 |
Koponen H et al. |
Computed tomography findings in delirium.
|
11 |
Koponen H et al. |
EEG spectral analysis in delirium.
|
12 |
Koponen H et al. |
Somatostatin-like immunoreactivity in the cerebrospinal fluid of chronic alcoholocs with cognitive impairment.
|
13 |
Koponen H, Riekkinen PJ. |
Delirium in the elderly. A review.
|
14 |
Koponen H et al. |
Cerebrospinal fluid somatostatin in delirium.
|
15 |
Koponen H et al. |
CSF beta-endorphin-like immunoreactivity in delirium.
|
16 |
Koponen H et al. |
Delirium among elderly persons admitted to a psychiatric hospital: Clinical course during the acute stage and one-year follow-up.
|
17 |
Kälviäinen R et al. |
A double blind study of gabapentin in treatment of partial seizures.
|
18 |
Kälviäinen R et al. |
Effects of gamma-vinyl GABA monotherapy oncognitive functioning in patients with newly diagnosed epilepsy.
|
19 |
Lepola U et al. |
On biological aspects of panic disorders.
|
20 |
Lepola U et al. |
Long-term effects of alprazolam and imipramine on cerebrospinal fluid monoamine metabolites and neuropeptides in panic disorder.
|
21 |
Matilainen R et al. |
Vigabatrin in epilepsy in mentally retarted patients.
|
22 |
Mervaala E et al. |
Somatosensory evoked potential dynamics in Baltic progressive myoclonus epilepsy.
|
23 |
Mervaala E et al. |
Electrophysiologic effects of Gamma-Vinyl GABA and Carbamazepine.
|
24 |
Nousiainen U et al. |
Videotelemetry, ambulatory and routine EEG in intractable seizure disorders.
|
25 |
Nousiainen U et al. |
Cardiac arrhythmias in the differential diagnosis of epilepsy.
|
26 |
Nousiainen U et al. |
The importance of the electrocardiogram in ambulatory electroencephalographic recordings.
|
27 |
Nousiainen U et al., ed. |
New trends in epilepsy and its treatment. Proceedings of the First Vaajasalo Epilepsy Symposium, Kuopio, May 18 and 19, 1989.
|
28 |
Pitkänen A. |
Somatostatin in experimental and human epilepsy.
|
29 |
Pitkänen A et al. |
Somatostatin, neuropeptide Y, GABA and cholinergic enzymes in brain of pentylenetetrazol-kindled rats.
|
30 |
Pitkänen A et al. |
Modulation of GABAergic transmission in the treatment of epilepsy.
|
31 |
Pitkänen A et al. |
Effect of cysteamine on somatostatin-like immunoreactivity in the amygdala-kindled rat brain.
|
32 |
Pitkänen A et al. |
The levels of somatostatin in the brain and CSF of rat after carbamazepine administration.
|
33 |
Pitkänen A et al. |
Somatostatinergic system and amygdala-kindling: Effect of cysteamine administration.
|
34 |
Pitkänen A et al. |
Somatostatin and beta-endorphin levels in cerebrospinal fluid of nonmedicated and medicated patients with epileptic seizures.
|
35 |
Pitkänen A et al. |
Inhibitory and excitatory amino acids in cerebrospinal fluid of chronic epileptic patients.
|
36 |
Pitkänen A et al. |
Effect of vigabatrin on epilepsy in mentally retarted patients: a 2-year follow-up study.
|
37 |
Pitkänen A et al. |
Effect of cysteamine on levels of somatostatin-like immunoreactivity and chatecholamines and on electroencephalogram in the rat brain.
|
38 |
Reinikainen KJ et al. |
2'3'-cyclic nucleotide phosphodiesterase activity as an index of myelin in the post-mortem brains of patients with Alzheimer's disease.
|
39 |
Reinikainen KJ, Riekkinen PJ. |
Noncholinergic neurotransmitter markers in the CSF of patients with dementia of Alzheimer type.
|
40 |
Riekkinen PJ et al. |
Specificity of Vigabatrin for the GABAergic system in human epilepsy.
|
41 |
Riekkinen PJ et al. |
Cerebrospinal fluid GABA and seizure control with vigabatrin.
|
42 |
Salmon DP et al. |
Cross-cultural studies of dementia.
|
43 |
Sirviö J. |
The cholinergic system in ageing and dementia with special reference to acetylcholinesterase.
|
44 |
Sirviö J et al. |
Cholinesterases in the cerebrospinal fluid, plasma and erythrocytes of patients with Alzheimer's disease.
|
45 |
Sirviö J et al. |
Brain cholinergic enzymes and cortical EEG activity in young and old rats.
|
46 |
Sirviö J et al. |
Age-dependence of the solubility fractions of acetylcholinesterase in the cerebral cortex and cerebellum of the rat.
|
47 |
Sirviö J et al. |
Different forms of brain acetylcholinesterase and muscarinic binding in Parkinson's disease.
|
48 |
Sivenius J. |
Ohimenevän aivoiskemian ennuste ja hoito.
|
49 |
Sivenius J. |
History of epilepsy treatment in Finland. History of neurology.
|
50 |
Soininen H et al. |
Longitudinal EEG spectral analysis in early stage of Alzheimer's disease.
|